[{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asana BioSciences Announces Topline Results from Phase 2b Study of Oral JAK\/SYK Inhibitor Gusacitinib in Patients with Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asana BioSciences to Present Positive Results from Phase 2b Study of Oral JAK\/SYK Inhibitor Gusacitinib in Patients with Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asana BioSciences to Present Additional Efficacy Data from Chronic Hand Eczema Phase 2b Trial of Gusacitinib at AAD VMX","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for Gusacitinib
Asana BioSciences will present additional positive results from a Phase 2b study evaluating the efficacy and safety of its investigational oral JAK kinase family and SYK tyrosine kinase inhibitor gusacitinib in adult patients with moderate-to-severe chronic hand eczema.
Gusacitinib achieved rapid, dose-dependent, clinically meaningful, and statistically significant improvement relative to placebo in both the primary and key secondary endpoints of efficacy as early as 2 weeks and the effects were sustained for the duration of the study.
The topline results show that gusacitinib achieved a dose dependent, clinically meaningful, andstatistically significant improvement relative to placebo in both the primary and key secondary endpoints of efficacy.